Adherence to glaucoma medication higher in the mornings

Article

Patient adherence to glaucoma medication could increase with morning application of glaucoma medication.

Patient adherence to glaucoma medication could increase with morning application of glaucoma medication, reveals a paper in the Journal of Glaucoma.

The prospective, randomized crossover treatment trial, conducted by Dr Bryce A. Ford et al., Department of Surgery, Division of Ophthalmology, University of Calgary, Alberta, Canada, involved 30 patients with glaucoma or ocular hypertension.

All patients initially received travoprost eye drops and were randomized to either morning or evening administration for one month. They were then crossed over to the opposite dosing schedule for the second month.

The main outcome measures were adherence between morning versus evening dosing and between first and second month dosing. Patients completed a post-study questionnaire on the convenience of the two dosing schedules.

Patient adherence overall was 89.3% and there was no significant difference between adherence for morning and evening dosing. However, patients claimed to prefer morning administration to evening administration and males were more likely to demonstrate a greater adherence for morning administration.

Adherence decreased from the first month to the second month and IOP response was not significantly affected by morning or evening administration.

The abstract can be read here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.